admin

Unico Silver Limited (“USL” or the “Company”) is pleased to report assay results for 31 holes (4,782m) as part of an ongoing drill program at the Company’s 100%-owned Joaquin Project in Santa Cruz, Argentina.

HIGHLIGHTS

Infill and extensional drilling at La Negra SE confirms broad, shallow zone of oxide silver-gold mineralisation over 850m strike and 175m vertical extent, open to the SE and at depth.
New standout drill results (from the SE of La Negra SE) include:

JDD0113-25	107m at 165gpt AgEq (1gpt Au, 70gpt Ag) from 18m, including: 55.6m at 245gpt AgEq (1.7gpt Au, 81gpt Ag) from 67.9m
JDD0118-25	74m at 134gpt AgEq (0.7gpt Au, 67gpt Ag) from 6m 35.6m at 207gpt AgEq (1.3gpt Au, 81gpt Ag) from 38.4m
JDD0108-25	81m at 107gpt AgEq (0.5gpt Au, 60gpt Ag) from 2m 15m at 183gpt AgEq (1.4gpt Au, 49gpt Ag) from 62m
JDD0112-25	46.2m at 117gpt AgEq (0.3gpt Au, 91gpt Ag) from 6.8m 27m at 145gpt AgEq (0.4gpt Au, 106gpt Ag) from 21m
JDD0111-25	58m at 100gpt AgEq (0.6gpt Au, 39gpt Ag) from 89m 7.45m at 1G3gpt AgEq (1.4gpt Au, 55gpt Ag) from 135m
JDD0123-25	56m at 106gpt AgEq (0.4gpt Au, 66gpt Ag) from 5m 10.7m at 1G5gpt AgEq (1.2gpt Au, 79gpt Ag) from 33.3m

True thickness ranges from 15 to 75 metres, supporting bulk open pit mining potential.
Drilling resumed 5 January 2026 and includes three diamond rigs and one Reverse Circulation (RC) rig. At La Negra SE, infill drilling on a 50m by 25m grid is nearing completion with 8 holes remaining to support a high confidence Indicated Resource.
Based on timing and new results, the Company will proceed directly to a Pre-Feasibility Study (PFS)-level Mineral Resource Estimate (MRE), covering La Negra, La Negra SE and La Morocha. Infill drilling at La Morocha SE will commence in February and is upside for future resource estimates and mining studies.
Regional exploration and soil geochemical sampling SE of La Morocha defines the 650m by 150m “La Rubia” silver anomaly (>2500ppb) confirming the potential for additional shallow discoveries along strike from La Morocha (Figure 3 to 4).

Managing Director Todd Williams states:

“Infill drilling at La Negra SE continues to deliver wide, shallow zones of oxide silver-gold mineralisation with excellent continuity across the full 850-metre strike length. These results confirm the scale and geometry required for conventional open-pit development and support our decision to move directly to a Pre-Feasibility Study Mineral Resource Estimate.

With infill drilling nearing completion, geotechnical and comminution programs already underway, and three key prospects – La Negra, La Negra SE and La Morocha – advancing to Indicated Resource status, Joaquin is rapidly transitioning from exploration to development while remaining open to further growth.”

Click here for the full ASX Release

This post appeared first on investingnews.com

Investing

Alvopetro Announces Record Sales Volumes

Alvopetro Energy Ltd. (TSXV: ALV,OTC:ALVOF) (OTCQX: ALVOF) announces December sales volumes of 2,826 boepd (based on field estimates). In Brazil, December sales averaged 2,687 boepd, including natural gas sales of 14.9 MMcfpd, associated natural gas liquids sales from condensate of 183 bopd and oil sales of 21 bopd. In Canada, December sales averaged 139 bopd. This brings our Q4 2025 sales volumes to 2,867 boepd, an increase of 22% over Q3 2025 and a new quarterly record for Alvopetro. 2025 sales volumes averaged 2,524 boepd, up 41% from 2024.

Natural gas, NGLs and crude oil sales:	December 2025	November 2025	Q4 2025	Q3 2025
Brazil:
Natural gas (Mcfpd), by field:
Caburé	9,833	9,881	9,653	8,735
Murucututu	5,069	5,242	5,439	3,558
Total natural gas (Mcfpd)	14,902	15,123	15,092	12,293
NGLs (bopd)	183	163	184	147
Oil (bopd) ⁽¹⁾	21	19	20	9
Total (boepd) – Brazil	2,687	2,702	2,719	2,205
Canada:
Oil (bopd) – Canada	139	149	148	138
Total Company – boepd⁽²⁾	2,826	2,851	2,867	2,343

(1)	Oil sales volumes in Brazil relate to the Bom Lugar and Mãe da lua fields. Alvopetro has entered into an assignment agreement to dispose of the fields, the closing of which is subject to standard regulatory approvals, including approval of the ANP.
(2)	Alvopetro reported volumes are based on sales volumes which, due to the timing of sales deliveries, may differ from production volumes.

Corporate Presentation

Alvopetro’s updated corporate presentation is available on our website at:
http://www.alvopetro.com/corporate-presentation.

Social Media

Follow Alvopetro on our social media channels at the following links:

X – https://x.com/AlvopetroEnergy
Instagram – https://www.instagram.com/alvopetro/
LinkedIn – https://www.linkedin.com/company/alvopetro-energy-ltd

Alvopetro Energy Ltd. is deploying a balanced capital allocation model where we seek to reinvest roughly half our cash flows into organic growth opportunities and return the other half to stakeholders. Alvopetro’s organic growth strategy is to focus on the best combinations of geologic prospectivity and fiscal regime. Alvopetro is balancing capital investment opportunities in Canada and Brazil where we are building off the strength of our Caburé and Murucututu natural gas fields and the related strategic midstream infrastructure.

Neither the TSX Venture Exchange nor its Regulation Services Provider (as that term is defined in the policies of the TSX Venture Exchange) accepts responsibility for the adequacy or accuracy of this news release.

Abbreviations:
boepd	=	barrels of oil equivalent (‘boe’) per day
bopd	=	barrels of oil and/or natural gas liquids (condensate) per day
Mcf	=	thousand cubic feet
Mcfpd	=	thousand cubic feet per day
MMcf	=	million cubic feet
MMcfpd	=	million cubic feet per day
NGLs	=	natural gas liquids (condensate)

BOE Disclosure

The term barrels of oil equivalent (‘boe’) may be misleading, particularly if used in isolation. A boe conversion ratio of six thousand cubic feet per barrel (6 Mcf/bbl) of natural gas to barrels of oil equivalence is based on an energy equivalency conversion method primarily applicable at the burner tip and does not represent a value equivalency at the wellhead. All boe conversions in this news release are derived from converting gas to oil in the ratio mix of six thousand cubic feet of gas to one barrel of oil.

www.alvopetro.com
TSX-V: ALV, OTCQX: ALVOF

SOURCE Alvopetro Energy Ltd.

View original content: http://www.newswire.ca/en/releases/archive/January2026/06/c9691.html

News Provided by Canada Newswire via QuoteMedia

This post appeared first on investingnews.com

Investing

Prismo Metals Announces Assay & IP Survey Results at Silver King

(TheNewswire)

Crown Porphyry-Stockwork Drill Targets Confirmed

Vancouver, British Columbia, January 7th, 2026 TheNewswire Prismo Metals Inc. (‘Prismo’ or the ‘Company’) (CSE: PRIZ,OTC:PMOMF) (OTCQB: PMOMF) is pleased to announce it has received final assay results for samples taken at the Silver King Project from the Crown porphyry target area located on the east side of the property (Fig. 1).

Click Image To View Full Size

Figure 1. Map showing the location of the Crown porphyry and stockwork and Black Diamond replacement exploration targets at the Silver King project. Claim boundaries are shown in yellow.

Overlimit silver assays have been received for the samples taken in late 2025, showing high grade silver mineralization associated with quartz-sulfide veins hosted by the Crown porphyry (Fig 2, Table 1). These assays provide evidence for a high-priority drill target, especially when taken in conjunction with the high gold assays reported previously for the stockwork intrusion (see the News Release of Dec. 3, 2025).

‘Prismo optioned Silver King with existing drill targets around the historically significant high-grade silver mine. Based on the geology and its location in a well mineralized region, we believed that additional mineralization was also likely present. Our work in the second half of 2025 indicates that we were correct, and we now have exceptional drill targets at the Crown porphyry and adjacent Black Diamond replacement areas,’ stated Craig Gibson, Chief Exploration Officer of the Company. He added, ‘With the high-grade gold assays reported in December and the copper assays at the Black Diamond replacement, we now have a very significant precious-metal and copper target at Silver King similar to other areas in this well mineralized district that includes the Magma mine and the Resolution copper deposit.’

‘These additional assay results along with the IP survey information continue to enhance and support our exploration thesis of the Silver King mine and surrounding areas,’ stated Gordon Aldcorn. ‘This modern-day review has yielded additional drill targets and prospective structures to our program in this already very strategically located project.’

Table 1. Assay results for selected samples from the Crown porphyry stockwork

Sample	Location	Easting	Northing	Width m	Au g/t	Ag g/t	Cu %	Pb %	Zn %
544559	Crown porphyry	492681	3687905	0.5 m	0.02	18.91	0.02	0.07	0.04
544561	Crown porphyry	492673	3687904	2 m	0.02	177	0.07	0.37	0.02
544563	Crown porphyry	492613	3687848	0.5m	0.03	176	–	0.09	0.01
544591*	Crown porphyry	492799	3687851	1.0	5.19	46.44	0.05	0.21	0.06
544592*	Crown porphyry	492793	3687823	1.0	4.06	13.97	0.02	0.10	0.07

*Assays previously released in News Release of December 3, 2025.

Click Image To View Full Size

Figure 2. Precious metal and copper assays from the Crown porphyry
and the Black Diamond replacement body at the Silver King Project.

IP Survey

The Company also completed a pole-dipole IP survey over a part of the Silver King project in December 2025. This survey was designed to provide some additional 3-dimensional data for areas identified during the initial gradient array survey (see News Release dated December 3, 2025). This new survey confirmed the presence of important chargeability and resistivity anomalies at the Silver King project. The Silver King silver mine appears to be associated with a large low resistivity anomaly located on the contact of the Silver King diorite porphyry (Fig 3). There is also low resistivity anomalies associated with the Crown porphyry and near the replacement mineralization at Black Diamond (Fig 3). The highest chargeability anomalies appear to be associated with the altered country rocks along intrusive contacts, but a chargeability high is also associated with the Crown porphyry stockwork intrusion. The anomaly associated with the Crown porphyry is particularly interesting and can be traced from shallow levels to about 300 meters in depth.

Click Image To View Full Size

Figure 3. IP resistivity map at a depth of 75 meters, overlain on geology and showing the Silver King glory hole (black line), Black Diamond replacement body in red, and the Crown porphyry-stockwork in magenta.

Click Image To View Full Size

Figure 4. IP chargeability at a depth of 75 meters, overlain on geology and showing the Silver King glory hole (black line), Black Diamond replacement body in red, and the Crown porphyry-stockwork in magenta.

Drilling Update

Alain Lambert, CEO of Prismo commented: ‘The results announced today confirm the vast exploration potential at Silver King. While we look forward to drilling these new targets in the future, our plans remain unchanged. Our immediate priority is to undertake our fully funded drill program, as previously announced. This drill campaign will primarily focus on the historic Silver King mine site and will be about 2,000 meters. The objective is to test the upper half of the steeply dipping pipelike Silver King mineralized body as well as potential mineralization adjacent to the dense stockwork that was the focus of historic mining.’

Mr. Lambert added: ‘We are pleased with the steady progress on the permitting front. The collaboration of Forest Service officials demonstrates a clear commitment to supporting mining activities in Arizona.’

Prismo recently announced that the Forest Service, the federal surface land management entity for Silver King, had determined that the Company’s proposed drill plan meets the regulatory requirements for processing, and that such plan is complete, as described in the regulations at 36 CFR 228.4(c).

The Forest Service is currently proceeding with the environmental analysis pursuant to 36 CFR 228(a)(5) in conformity with the National Environmental Policy Act (NEPA). This analysis is proceeding as a Categorical Exclusion, the lowest level of environment reviews applicable to projects that are not expected to have a significant effect on the environment, such as Silver King.

QA/QC

Samples were analyzed by SGS, an internationally recognized analytical lab, with preparation at the Tempe, Arizona facility and analyses at the Burnaby laboratory. Prismo inserts controls samples consisting of a standard pulps and a coarse blanks in the sample stream, and the lab also inserts control samples.

Qualified Person

Dr. Craig Gibson, PhD., CPG., a Qualified Person as defined by NI-43-01 regulations and Chief Exploration Officer and a director of the Company, has reviewed and approved the technical disclosures in this news release.

About Prismo Metals Inc.

Prismo (CSE: PRIZ,OTC:PMOMF) is a mining exploration company focused on advancing its Silver King, Ripsey and Hot Breccia projects in Arizona and its Palos Verdes silver project in Mexico.

Please follow @PrismoMetals on Twitter, Facebook, LinkedIn, Instagram, and YouTube

Prismo Metals Inc.

1100 – 1111 Melville St., Vancouver, British Columbia V6E 3V6 Phone: (416) 361-0737

Contact:

Alain Lambert, Chief Executive Officer alain.lambert@prismometals.com

Gordon Aldcorn, President gordon.aldcorn@prismometals.com

Neither the Canadian Securities Exchange nor its Market Regulator (as that term is defined in the policies of the Canadian Securities Exchange) accepts responsibility for the adequacy or accuracy of this release.

Cautionary Note Regarding Forward-Looking Information

This release includes certain statements and information that may constitute forward-looking information within the meaning of applicable Canadian securities laws. Forward-looking statements relate to future events or future performance and reflect the expectations or beliefs of management of the Company regarding future events. Generally, forward-looking statements and information can be identified by the use of forward-looking terminology such as ‘intends’ or ‘anticipates’, or variations of such words and phrases or statements that certain actions, events or results ‘may’, ‘could’, ‘should’, ‘would’ or ‘occur’. This information and these statements, referred to herein as ‘forward-looking statements’, are not historical facts, are made as of the date of this news release and include without limitation, statements regarding discussions of future plans, estimates and forecasts and statements as to management’s expectations and intentions with respect to, among other things: the timing, costs and results of drilling at Silver King; and the intended use of any proceeds raised under recent financings.

These forward-looking statements involve numerous risks and uncertainties, and actual results might differ materially from results suggested in any forward-looking statements. These risks and uncertainties include, among other things: the potential inability of the Company to utilize the anticipated proceeds of the Private Placement as anticipated; and those risks set out in the Company’s public disclosure record on SEDAR+ (www.sedarplus.com) under the Company’s issuer profile.

In making the forward-looking statements in this news release, the Company has applied several material assumptions, including without limitation, that the Company will use the proceeds of the Second Tranche as currently anticipated and on the timeline currently expected.

Although management of the Company has attempted to identify important factors that could cause actual results to differ materially from those contained in forward-looking statements or forward- looking information, there may be other factors that cause results not to be as anticipated, estimated or intended. There can be no assurance that such statements will prove to be accurate, as actual results and future events could differ materially from those anticipated in such statements. Accordingly, readers should not place undue reliance on forward-looking statements and forward- looking information. Readers are cautioned that reliance on such information may not be appropriate for other purposes. The Company does not undertake to update any forward-looking statement, forward-looking information or financial outlook that are incorporated by reference herein, except in accordance with applicable securities laws. We seek safe harbor.

News Provided by TheNewsWire via QuoteMedia

This post appeared first on investingnews.com

Investing

Top 3 Small-cap Medical Device Stocks (Updated January 2026)

The growing prevalence of chronic diseases like cancer and diabetes is driving increasing innovation in medical device technology. In 2024 alone, 30 new devices were approved by the US Food and Drug Administration (FDA).

Wearable medical devices and the use of artificial intelligence in medical technology are two key trends in this sector.

Investors who want exposure to this wave of growth may want to consider NASDAQ small-cap medical device stocks. Below is a list of the top NASDAQ medical device companies based on year-on-year gains.

All data was compiled on December 31, 2025, using TradingView’s stock screener, and the medical device makers listed below had market caps between US$50 million and US$500 million at that time.

1. MDxHealth (NASDAQ:MDXH)

Year-on-year gain: 50.86 percent
Market cap: US$173.24 million
Share price: US$3.50

MDxHealth is a commercial-stage precision diagnostics company specializing in molecular tests for urologic cancers, particularly prostate cancer, using genomic, epigenetic and exosomal technologies. Its US headquarters and operations are located in Irvine, California.

The company offers non-invasive and tissue-based diagnostic assays that run on standard PCR platforms.

In September, MDxHealth acquired Exosome Diagnostics from Bio-Techne (NASDAQ:TECH) for US$15 million, adding the ExoDx Prostate urine test to its portfolio. The deal also includes a CLIA-certified clinical laboratory and related assets. The deal is expected to generate over US$20 million in revenue in 2026.

2. KORU Medical Systems (NASDAQ:KRMD)

Year-on-year gain: 50.13 percent
Market cap: US$269.6 million
Share price: US$5.82

KORU Medical Systems develops and manufactures medical devices and supplies in the US and internationally, with a focus on mechanical infusion products. Its Freedom Syringe Infusion System first received FDA clearance in 1994.

Based on this system, its primary products include the Freedom60 and FreedomEdge syringe infusion systems, Precision Flow Rate Tubing and High-Flo Subcutaneous Safety Needle Sets.

KORU Medical Systems submitted a 510(k) premarket notification to the FDA on December 30, 2025, seeking clearance for its FreedomEdge system to deliver Phesgo — a HER2+ breast cancer targeted biologic — subcutaneously, targeting infusion centers to cut chair time and boost efficiency.

The company stated this is part of its strategy to expand the indications of FreedomEdge to the wider oncology infusion center market.

3. Vivani Medical (NASDAQ:VANI)

Year-on-year gain: 1.71 percent
Market cap: US$86.81 million
Share price: US$1.19

Vivani Medical is a clinical-stage biopharmaceutical company developing miniature, long-term subdermal drug implants using its proprietary NanoPortal technology to treat chronic conditions like obesity and type 2 diabetes.

Headquartered in Alameda, California, Vivani focuses on GLP-1 implants that provide steady drug release over six months to improve adherence and tolerability compared to daily pills or weekly injections.

In August, Vivani Medical reported positive Phase 1 results from its LIBERATE-1 trial of the NPM-115 exenatide implant, confirming safety and steady drug release for obesity treatment without major side effects.

The company plans to rapidly advance its NPM-139 semaglutide implant after it achieved preclinical results of sustained 20 percent weight loss. It is planning a Phase 1 clinical study in the first half of 2026.

Securities Disclosure: I, Meagen Seatter, hold no direct investment interest in any company mentioned in this article.

This post appeared first on investingnews.com

Investing

Locksley Resources LimitedIdentifies High-Grade Silver Corridor at the Mojave Project

Sydney, Australia (ABN Newswire) – Locksley Resources Limited (ASX:LKY,OTC:LKYRF) (FRA:X5L) (OTCMKTS:LKYRF) advised that recent reconnaissance and surface sampling programs have successfully identified a consistent northwest to southeast oriented mineralised corridor at the Mojave Project.

HIGHLIGHTS

– Results from rock chip sampling returns 409g/t Ag confirming high-grade silver mineralisation ~3km from the initial high-grade silver discovery (Sample 258140), 320m southwest of the Desert Antimony Mine (DAM)

– Significant base metal mineralisation confirmed in addition to silver, with samples returning grades up to 4.2% Copper (Cu), 1.5% Lead (Pb), and 1.5% Zinc (Zn), highlighting the polymetallic nature of the system

– Twelve (12) rock chip samples exceeded 30g/t Ag, reinforcing additional precious and base metal potential within the Mojave Project’s North Block

– This discovery represents an important advancement in the Company’s exploration strategy and identifies a new, potentially high-value component of the Mojave Project

This discovery represents an important advancement in the Company’s exploration strategy and identifies a new, potentially high-value component of the Mojave Project. The delineation of a mineralised corridor suggests a strike extent approximately 2.4km westnorthwest of the Hendricks Shaft, and approximately 600m to the east-southeast, extending the mineralised corridor almost 3km from the Silver Prospect. This confirms the presence of a polymetallic quartz vein system, which includes the high-grade sample 258140 collected from a 3cm to 10cm wide vein (Figure 1*). These early results possibly suggest that the Ag-Pb-Zn-Cu mineralisation may reflect the presence of a large-scale hydrothermal system, which could potentially contain valuable concentrations of precious and base metals. Further exploration is required to test this concept.

Rock chip sampling within the Mojave Project’s North Block has returned results of up to 409g/t Ag, with associated base metal values of up to 1.5% Zn and 0.88% Pb, supporting the interpretation of a polymetallic mineralised system and enhancing the prospectivity of the corridor. Additional rock chip sample 258420 returned values up to 117g/t Ag, & 3.1% Cu, also located within the interpreted mineralised corridor located close to a historic adit and workings.

The interpreted mineralised corridor includes the historic Hendricks Shaft, located approximately 2.4km from the initial high-grade silver discovery. A total of 398 rock chip samples have been collected across the North Block with ~260 of these being collected along the mineralised corridor between DAM and up to 5.6km to the southeast.

Rock Chip Sampling Program Details

The recent sampling campaign was designed to test the strike extent of the high-grade silver mineralisation first identified in late 2024. The results (see Table 1) have exceededexpectations, confirming that the mineralised system extends significantly beyond the initial discovery zone (Sample 258140 – Figure 1*).

Key observations from the program include:

– Strike Extension: The mineralised corridor is now interpreted to extend from the Silver Prospect (Sample 258140) to historical trenches and stockpiles (Samples 258184 & 258185) located ~3km to the south-east significantly increasing the strike extent of the exploration target.

– Mineralisation Style: High-grade samples 258184 and 258185, collected from outcropping veins and historic stockpiles, exhibit quartz with gossanous selvages with boxwork textures. These are potential indicators of weathered sulphide-rich polymetallic veins, suggesting fresh sulphides may exist at depth.

– Visual Copper: Sample 258420 (which returned 117g/t Ag & 3.1% Cu) was collected from outcropping mineralisation at historic workings where copper carbonate (i.e. malachite) is visually prevalent (see Figure 3*). This confirms a copper component to the mineralised system.

Next Steps

Locksley will advance this exciting silver and base metal opportunity through a systematic exploration program run in parallel with ongoing activities at DAM and El Campo, comprising:

– Systematic Mapping: Detailed geological mapping between the Silver Prospect and the new south-eastern extension to define the structural geometry and continuity of the trend.

– Petrology and Geochemistry: Submission of samples for petrological interpretation to assist with determining relative timing of mineralisation and geochemical associations across the system.

– Geophysics: Assessment of geophysical survey options, such as Very Low Frequency electromagnetics (VLF-EM), Induced Polarisation (IP), or Electromagnetic (e.g. VTEM) to potentially identify mineralised zones and structures at depth that are not visible at surface.

– Drill Targeting: The goal of this work is to delineate high-priority drill-ready targets along the NW-SE corridor for future testing.

Additional work is planned to improve understanding of the corridor’s structural geometry, enabling more effective drill targeting and delineation of the extent and grade of mineralisation within the North Block.

Kerrie Matthews, Managing Director & CEO, commented:

‘Defining a 3km mineralised trend with surface results of up to 409 g/t silver and 1.5% copper is a highly encouraging outcome. Importantly, this discovery complements our core antimony development strategy and gives exposure as a diversified U.S. critical minerals company, providing shareholders with upside to precious metals, base metals, and strategic minerals within a single, high-quality project area.’

*To view tables and figures, please visit:
https://abnnewswire.net/lnk/R8C037M3

About Locksley Resources Limited:

Locksley Resources Limited (ASX:LKY,OTC:LKYRF) (FRA:X5L) (OTCMKTS:LKYRF) is an ASX listed explorer focused on critical minerals in the United States of America. The Company is actively advancing exploration across two key assets: the Mojave Project in California, targeting rare earth elements (REEs) and antimony. Locksley Resources aims to generate shareholder value through strategic exploration, discovery and development in this highly prospective mineral region.

Mojave Project

Located in the Mojave Desert, California, the Mojave Project comprises over 250 claims across two contiguous prospect areas, namely, the North Block/Northeast Block and the El Campo Prospect. The North Block directly abuts claims held by MP Materials, while El Campo lies along strike of the Mountain Pass Mine and is enveloped by MP Materials’ claims, highlighting the strong geological continuity and exploration potential of the project area.

In addition to rare earths, the Mojave Project hosts the historic ‘Desert Antimony Mine’, which last operated in 1937. Despite the United States currently having no domestic antimony production, demand for the metal remains high due to its essential role in defense systems, semiconductors, and metal alloys. With significant surface sample results, the Desert Mine prospect represents one of the highest-grade known antimony occurrences in the U.S.

Locksley’s North American position is further strengthened by rising geopolitical urgency to diversify supply chains away from China, the global leader in both REE & antimony production. With its maiden drilling program planned, the Mojave Project is uniquely positioned to align with U.S. strategic objectives around critical mineral independence and economic security.

Tottenham Project

Locksley’s Australian portfolio comprises the advanced Tottenham Copper-Gold Project in New South Wales, focused on VMS-style mineralisation

Source:
Locksley Resources Limited

Contact:
Kerrie Matthews
Chief Executive Officer
Locksley Resources Limited
T: +61 8 9481 0389
Kerrie@locksleyresources.com.au

News Provided by ABN Newswire via QuoteMedia

This post appeared first on investingnews.com

Investing

David Morgan: Silver’s Price Breakout — What’s Next, Key Drivers

David Morgan, publisher of the Morgan Report, weighs in on silver’s record-setting price rise and what could be next for the white metal heading into 2026.

‘We’re still in price discovery. I truly believe that,’ he said.

‘What the true price of silver is in US dollars, Canadian dollars, I do not know. I think it’s north of $100 in US dollar terms, but it could be much higher than that.’

Securities Disclosure: I, Charlotte McLeod, hold no direct investment interest in any company mentioned in this article.

This post appeared first on investingnews.com

Investing

Top 5 Small-cap Pharma Stocks (Updated January 2026)

Today’s pharmaceutical stocks are facing the challenges of government-imposed drug price caps, waning demand for COVID-19 vaccines and global stock market upheaval.

However, the industry’s major underlying drivers — higher rates of cancer and chronic disease — are still at play and not expected to dissipate.

The US reigns supreme in the pharma market, both in terms of drug demand and development. In 2025, 46 novel medicines were approved by the US Food and Drug Administration (FDA), compared to 50 such approvals in 2024.

Big pharma largely steals the show when people discuss pharmaceutical companies, but some small- and mid-cap NASDAQ pharma stocks have also made gains.

Read on to learn more about their activities this year.

1. Galectin Therapeutics (NASDAQ:GALT)

Year-to-date gain: 211.45 percent
Market cap: US$263.08 million
Share price: US$4.08

Galectin Therapeutics is developing therapies for patients with chronic liver disease and cancer.

The clinical-stage biopharma company’s lead drug candidate, carbohydrate-based belapectin, targets multiple inflammatory, fibrotic and malignant diseases by inhibiting the galectin-3 protein. Belapectin has been granted fast-track designation by the FDA.

In 2025, Galectin Therapeutics reported positive topline data from its Phase 2b/3 trial evaluating the efficacy and safety of using belapectin intravenously in patients with metabolic dysfunction-associated steatohepatitis (MASH) cirrhosis and portal hyper tension. The results demonstrated that belapectin significantly reduced the development of new esophageal varices and stabilized liver stiffness, demonstrating potential to halt the progression of MASH cirrhosis.

Galectin is currently designing its pivotal Phase 3 study intended to support a formal new drug application. Based on a December 2025 response from the FDA, the company said it believes it has achieved alignment with the agency on the patient population for its upcoming registration-level trials.

2. CytomX Therapeutics (NASDAQ:CTMX)

Year-to-date gain: 136.63 percent
Market cap: US$375.74 million
Share price: US$2.38

CytomX Therapeutics is a clinical-stage biopharma firm with a focus on developing safer, more effective oncology treatments. It collaborates with a number of leading oncology firms, including Amgen (NASDAQ:AMGN), Bristol-Myers Squibb (NYSE:BMY), Regeneron Pharmaceuticals (NASDAQ:REGN) and Moderna (NASDAQ:MRNA).

The company’s pipeline is based on its PROBODY therapeutic platform, which it uses to produce localized biologics that target tumors. This includes multiple treatment modalities such as antibody-drug conjugates, T-cell engagers and immune modulators such as cytokines. Its clinical-stage pipeline includes CX-2051 and CX-801.

In mid-May 2025, CytomX’s share price shot up significantly after the company provided its Q1 business update and closed on a US$100 million underwritten offering of common stock.

In the update, CytomX included positive interim clinical results for an ongoing Phase 1 dose escalation study of its lead candidate, CX-2051, in advanced colorectal cancer. The company has initiated further Phase 1 dose expansions, with data expected out by Q1 2026. In its Q3 update, CytomX reported it plans to initiate a Phase 1b study of CX-2051 in combination with bevacizumab to treat colorectal cancer, also expected in the first quarter of the new year.

On May 19, the first patient was dosed in CytomX’s ongoing Phase 1 dose escalation study with CX-801 in combination with Merck & Company’s (NYSE:MRK) Keytruda in patients with metastatic melanoma. The company released initial translational data in November.

3. Eton Pharmaceuticals (NASDAQ:ETON)

Year-to-date gain: 25.37 percent
Market cap: US$450.53 million
Share price: US$16.80

Eton Pharmaceuticals is a high-growth pharmaceutical company developing treatments for rare diseases. Headquartered in Deer Park, Illinois, the company has successfully transitioned from a development-stage firm into a commercially focused entity with a diversified portfolio of orphan drugs.

2025 included the successful launch of KHINDIVI, the first FDA-approved oral solution formulation of hydrocortisone, in June. KHINDIVI was approved in May for pediatric patients five and older with adrenocortical insufficiency. The company is looking to expand the indication to younger patients with a revised formulation, and a bioequivalence study is expected to begin in early 2026.

The year also included high-performing relaunches of acquired assets Increlex, which treats a rare condition in which a child’s body does not produce enough growth factor-1, and the zinc therapy Galzin, a maintenance treatment for Wilson disease.

As of December, its portfolio included eight commercial products and five in its pipeline. The FDA is reviewing its new drug application for ET-600, with a decision scheduled for late February.

4. Fennec Pharmaceuticals (NASDAQ:FENC)

Year-to-date gain: 20.91 percent
Market cap: US$262.54 million
Share price: US$7.69

Fennec Pharmaceuticals is a commercial-stage specialty pharmaceutical company focused on preventing ototoxicity, meaning permanent hearing loss, in pediatric cancer patients undergoing cisplatin-based chemotherapy.

The company’s sole commercial product, Pedmark, is the first and only FDA-approved therapy specifically indicated to reduce the risk of hearing loss associated with cisplatin in patients one month of age and older with non-metastatic solid tumors.

Fennec experienced a pivotal year in 2025, marked by record revenue growth, entry into international markets and the elimination of corporate debt.

Additionally, data from a Phase 2/3 clinical study in Japan showed a significant reduction in the percentage of patients who experienced hearing loss, setting the stage for a 2026 global registration.

The company also began exploring its first major expansion into the adult cancer market through a new trial in metastatic testicular cancer.

5. Zevra Therapeutics (NASDAQ:ZVRA)

Year-to-date gain: 5.25 percent
Market cap: US$496.54 million
Share price: US$8.82

Zevra Therapeutics is a commercial-stage rare disease company that utilizes data-driven strategies to develop and commercialize transformational therapies for ultra-rare conditions.

Formerly known as KemPharm, the company rebranded in 2023 to reflect its evolution into a fully integrated pharmaceutical entity with a focus on high-unmet-need pediatric and metabolic disorders.

At the end of December, Zevra executed a strategic distribution agreement with Uniphar to provide its flagship product, Miplyffa, to patients outside of the US and Europe, broadening the drug’s global footprint. Miplyffa was approved by the FDA in 2024, and is indicated as a treatment for Niemann-Pick disease type C administered in combination with miglustat.

This announcement followed a strong Q3, in which the company reported a 605 percent year-over-year revenue increase, largely driven by the early success of Miplyffa.

Securities Disclosure: I, Meagen Seatter, hold no direct investment interest in any company mentioned in this article.

This post appeared first on investingnews.com

Investing

High Grade Mineralised Corridor at the Mojave Project

Locksley Resources (LKY:AU) has announced High Grade Mineralised Corridor at the Mojave Project

Download the PDF here.

This post appeared first on investingnews.com

Investing

Altech Batteries LtdCERENERGY Project Secures German Grant Approval

Perth, Australia (ABN Newswire) – Altech Batteries Ltd (ASX:ATC,OTC:ALTHF) (FRA:A3Y) (OTCMKTS:ALTHF) announced that binding conditional funding approval in the amount of 46.11 million Euro has now been granted for the CERENERGY(R) Sodium-Chloride Solid-State battery project in Saxony, Germany. The grant approval materially derisks project funding and supports progression toward construction of the planned 120 MWh CERENERGY(R) battery manufacturing facility in Saxony, Germany.

Highlights

– Altech Batteries GmbH’s CERENERGY(R) battery project has received conditional binding funding approval under Germany’s federal ‘STARK’ economic development program.

– The approval relates to a grant covering approximately 30% of eligible project CAPEX, with funding of up to EUR46.11M.

– The funding commitment is conditional on achieving full project financial close by 30 June 2026 and parliamentary approval of funds under Germany’s 2026 Federal Budget.

Conditional Binding Funding Commitment

The funding is being provided as part of the federal STARK program, which is supported by the Federal Ministry for Economic Affairs and Energy in cooperation with the EU. The aim of this program is to lead regions undergoing structural change into an ecologically, economically and socially sustainable future.

With the approval of the funding, the project has successfully completed the second and decisive stage of the approval process. The funding covers approximately 30% of the eligible investment costs and represents a significant milestone for the construction of the planned 120 MWh CERENERGY(R) battery factory in Germany.

This decision underscores the importance of the innovative CERENERGY(R) technology, which is being developed in collaboration with the Fraunhofer Society. The Sodium-Chloride Solid-State battery offers a safe, sustainable and strategically independent alternative to lithium-ion batteries and is expected to play an important role in future stationary energy storage solutions – especially for the European market.

Mr Daniel Raihani, Managing Director & Chief Executive Officer, commented ‘Securing conditional binding funding approval of up to EUR46.11 million under Germany’s STARK program is a major milestone for the CERENERGY(R) project. The support reflects the strategic importance of establishing advanced, nonlithium energy storage manufacturing capability in Europe and recognises the technical progress achieved to date in collaboration with Fraunhofer IKTS.

‘Importantly, the grant materially de-risks the project’s capital structure by covering approximately 30% of eligible investment costs and provides a strong foundation as we progress toward full project financing and construction of the planned 120 MWh production facility in Saxony, Germany.

‘We remain focused on completing financial close by mid-2026 and advancing the CERENERGY(R) technology toward commercial deployment to support long-duration, safe and sustainable stationary energy storage solutions for the European market’.

As is customary for projects of this size, the funding commitment is subject to final financial close of the CERENERGY(R) battery project by June 2026 and budgetary approval of the funds in the 2026 federal budget.

*To view tables and figures, please visit:
https://abnnewswire.net/lnk/918BT5H8

About Altech Batteries Ltd:

Altech Batteries Limited (ASX:ATC,OTC:ALTHF) (FRA:A3Y) is a specialty battery technology company that has a joint venture agreement with world leading German battery institute Fraunhofer IKTS (‘Fraunhofer’) to commercialise the revolutionary CERENERGY(R) Sodium Alumina Solid State (SAS) Battery. CERENERGY(R) batteries are the game-changing alternative to lithium-ion batteries. CERENERGY(R) batteries are fire and explosion-proof; have a life span of more than 15 years and operate in extreme cold and desert climates. The battery technology uses table salt and is lithium-free; cobalt-free; graphite-free; and copper-free, eliminating exposure to critical metal price rises and supply chain concerns.

The joint venture is commercialising its CERENERGY(R) battery, with plans to construct a 100MWh production facility on Altech’s land in Saxony, Germany. The facility intends to produce CERENERGY(R) battery modules to provide grid storage solutions to the market.

Source:
Altech Batteries Ltd

Contact:
Daniel Raihani
Managing Director
Altech Batteries Limited
Tel: +61-8-6168-1555
Email: info@altechgroup.com

Martin Stein
Chief Financial Officer
Altech Batteries Limited
Tel: +61-8-6168-1555
Email: info@altechgroup.com

News Provided by ABN Newswire via QuoteMedia

This post appeared first on investingnews.com

Investing

Juggernaut Exploration

Investor Insight

Juggernaut Exploration is an early-stage explorer and project generator with a compelling investment story, focused on unlocking high-grade precious and base metal discoveries in the prolific Golden Triangle of northwestern British Columbia.

Overview

Juggernaut Exploration(TSXV:JUGR,OTCQB:JUGRF,FSE:4JE) is a precious metals explorer focused on northwestern British Columbia’s Golden Triangle, a globally recognized district for world-class porphyry, VMS, and high-grade gold systems. The company operates in a geopolitically stable jurisdiction with excellent infrastructure, adjacent to Newmont’s Galore Creek project and in proximity to major road and airstrip developments.

The company controls three 100 percent owned projects – Big One, Midas, and Bingo – totaling nearly 60,000 hectares in the heart of British Columbia’s most prolific mineral belt.

The company’s current strategy focuses on aggressive exploration at its flagship Big One project, where the rapid abatement of glacial cover led to the discovery of over 200 mineralized veins in a matter of days. The scale of the system, coupled with strong geophysical and geochemical signatures, points to a significant buried porphyry system.

Backed by world-renowned geologist Dr. Quinton Hennigh, Juggernaut was founded by the team behind Goliath Resources, which returned 2,400 percent to early investors in just 20 months.

Company Highlights

The Big One property has uncovered a 15-km gold-rich porphyry system, described as a “highway of gold,” adjacent to Newmont’s $100 billion Galore Creek project.
Founded by the team behind Goliath Resources, which returned 3,400 percent to early investors in just 20 months. World-renowned geologist Dr. Quinton Hennigh supports Juggernaut.
Crescat Capital is a cornerstone investor, holding a 19.99 percent stake and providing both financial and technical backing.
The company controls three 100 percent owned projects – Big One, Midas, and Bingo – totaling nearly 60,000 hectares in the heart of the Golden Triangle in British Columbia.
With $12.5 million recently raised, the 2025 field season is fully funded. The upcoming campaign aims to scale and define the scope of the porphyry system discovered in just five days of boots-on-the-ground work.
5-Year Drill Permit Secured: A valid 5-year drill permit is in place for the Big One Property in British Columbia’s Golden Triangle, in good standing through March 31, 2031.
2026 Inaugural Drill Program: The company is planning a fully funded drill program to test multiple gold-rich, shear-hosted vein targets identified at surface within the newly discovered, district-scale Eldorado System and Gold Swarm discoveries, targeting depth extensions in the third dimension.
Over 70 percent of the company’s shares are held by management, insiders and accredited investors. The company is debt-free.

Key Projects

Big One

The Big One project is Juggernaut’s flagship asset located in the heart of British Columbia’s Golden Triangle. The property spans 36,989 hectares of world-class geological terrain, with 95 percent of its remaining unexplored.

The project benefits from rapid glacial and snowpack abatement, which has recently exposed a vast mineralized system previously hidden under ice. This includes the newly identified Eldorado porphyry system, a high-grade, multi-kilometer corridor with grades reaching up to 79.01 grams per ton (g/t) gold and 3,157 g/t silver. More than 200 quartz-sulphide veins, containing semi-massive to massive chalcopyrite, sphalerite and galena, have been identified within a 4 km x 1 km alteration footprint, with coincident geophysical anomalies suggesting the presence of a large, buried mineralizing system at depth.

The Big One project qualifies for the Critical Mineral Exploration Tax Credit and is strategically located adjacent to key infrastructure, including the Scud airstrip and a new $45 million government-funded road within 12 km of the site.

In 2025, Juggernaut Exploration received a 5-year drill permit for the Big One property. The permit is in good standing until March 31, 2031. The company is planning a drill program targeting several extensive gold-rich shear-hosted veins confirmed on surface in the newly discovered district-scale Eldorado System and Gold Swarm discoveries. These strong drill targets are planned to be tested in the third dimension during the fully-funded inaugural drill program in 2026.

Newly discovered drill ready El Dorado System

Midas

The Midas property covers 20,803 hectares in a geologically favorable setting for volcanogenic massive sulphide (VHMS) deposits, particularly those resembling the high-grade Eskay Creek system. Drilling at the Kokomo zone has intercepted significant VHMS-style mineralization, including standout results such as 8.27 g/t gold equivalent over 11.03 meters (MD-24-47) and 6.85 g/t gold over 9 meters (MD-18-08). The mineralized zone remains open to the north, and the company plans to step out aggressively with additional drilling.

Midas is considered a strong near-term value generator with potential for scale through further discovery.

Bingo

The Bingo property, although smaller in footprint at 1,008 hectares, is located in a structurally favorable setting for shear-hosted gold systems. The project features a 700-meter x 400-meter mineralized zone characterized by consistent sulphide mineralization. Sampling has confirmed an average mineralized width of 7 meters with grades averaging 5.67 g/t gold equivalent. The presence of strong K-spar alteration in the northeast quadrant of the property suggests proximity to a porphyry feeder system, making Bingo a compelling target for both high-grade, shear-hosted and porphyry-style exploration.

Management Team

Manuele (Lele) Lazzarotto – President and Chief Operating Officer (COO)

Manual Lazzarotto, Ph.D., has over a decade of experience in the mineral exploration industry, taking projects from inception to defined deposits. He has extensive experience in volcanogenic massive sulphide deposits and gold systems in Canada. Most recently, Lazzarotto has acted as chief geologist, instrumental in the discovery of Goliath Resources’ Surebet Discovery from 2019 to 2025. He holds a BSc and an MSc in Earth Sciences from ETH Zurich, Switzerland, and a PhD in Metamorphic Petrology from the University of Calgary, Canada.

Dan Stuart – CEO and Director

Dan Stuart has over 30 years of experience in capital markets, having raised more than $500 million for natural resource companies. He is a founding member and financier of several private mineral syndicates, including the J2 Syndicate behind Goliath Resources. Stuart is recognized for his investor acumen and has established strong institutional relationships across North America, Europe, Asia, and the Middle East. Under his leadership, Juggernaut secured cornerstone funding from Crescat Capital and Dr. Quinton Hennigh while simultaneously building a platform for rapid discovery-driven growth.

Jim McCrea – Director

Jim McCrea brings 25 years of exploration and resource estimation experience. Notably, he worked on orebody modeling and resource estimation at Cumberland Resources, which was acquired by Agnico Eagle for $710 million. His deep expertise in geology and modeling helps guide exploration targeting and resource development.

William Jung – Director and CFO

A former chartered accountant with over 35 years of experience in finance, William Jung has managed several publicly listed companies on the TSX. His oversight ensures financial discipline, compliance, and strategic capital allocation.

Peter Bryant – Director

Peter Bryant is a seasoned international investment banker with 45 years of experience, including senior roles at Standard Chartered Group, Hill Samuel Group, and Guinness Mahon Holdings in London. His presence brings strong governance and capital markets insights to the board.

Chris Verrico – Director

Chris Verrico has over two decades of experience managing mineral exploration and infrastructure projects in remote northern regions, including British Columbia, Yukon and Nunavut. His knowledge of field operations and community engagement is critical to project execution.

Bill Chornobay – Program Manager

Bill Chornobay has over 30 years of experience in mineral exploration and has been directly involved in discoveries resulting in more than $1 billion in value. He played a pivotal role in the Surebet discovery for Goliath Resources and now leads on-ground execution at Juggernaut.

Dr. Quinton Hennigh – Technical Advisor

A globally respected exploration geologist, Dr. Quinton Hennigh has over 30 years of experience with major mining companies, including Homestake, Newcrest and Newmont. He is currently the chairman of Novo Resources and serves as a technical advisor to Crescat Capital. His guidance has helped validate and shape the exploration strategy at Juggernaut.

Dr. Manuele Lazzarotto – Senior Consulting Geologist

Dr. Manuele Lazzarotto has eight years of experience advancing early-stage exploration projects into defined resources, particularly in VMS and gold systems. He played a critical technical role in the Surebet discovery and brings valuable geological and structural insight to Juggernaut’s targeting approach.

This post appeared first on investingnews.com